Clinical Trial Update: Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on combining sintilimab with stereotactic body radiotherapy (SBRT) in hepatocellular carcinoma (HCC) across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Mian XI | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN